HCWB HCW Biologics Inc.
USHealthcareAs of 2026-07-10 16:00
Why HCWB matters now
HCW Biologics Inc. (HCWB) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.55 with -2.05% on the session and $1.6M in market capitalization; recent performance reads 1-month +2.83% and YTD +12.30%.
The latest financial table shown here is Q1 2026, with revenue of $6.5M, net income of $4.1M, and EPS of $1.97. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -503.7%.
The latest indexable market news headline is "HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Byam Rebecca filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.40
P/S
0.34
EV/EBITDA
-12.61
DCF Value
$-7.65
FCF Yield
-503.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-97.9%
Net Margin
-24.7%
ROE
-102.4%
ROA
-6.0%
ROIC
-38.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.5M | $4.1M | $1.97 |
| Q4 2025 | $27.0K | $719.2K | $-1.65 |
| FY 2025 | $54.2K | $-8.0M | $-10.63 |
| Q3 2025 | $15.6K | $-4.6M | $-2.02 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.21
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.